Pleural Malignant Mesothelioma clinical trials
16 active trials name this condition. Describe your situation to see which ones you may be eligible for.
Refine by biomarker
By location
- Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma
- Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)
- Partial Pleurectomy (Surgery) for Unresectable Pleural Mesothelioma
- A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
- CT-95 in Advanced Cancers Associated With Mesothelin Expression
- Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
- A Study of NX-1607 in Adults With Advanced Malignancies
- A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
- Clinical Trial of PM54 in Advanced Solid Tumors Patients.
- A Beta-only IL-2 ImmunoTherapY Study
- Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma
- Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers
- Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining
- OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition
- MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Pleural Malignant Mesothelioma” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.